Is OKYO Pharma Stock a Good Investment?
OKYO Pharma Investment Advice | OKYO |
- Examine OKYO Pharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research OKYO Pharma's leadership team and their track record. Good management can help OKYO Pharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact OKYO Pharma's business and its evolving consumer preferences.
- Compare OKYO Pharma's performance and market position to its competitors. Analyze how OKYO Pharma is positioned in terms of product offerings, innovation, and market share.
- Check if OKYO Pharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about OKYO Pharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in OKYO Pharma Ltd stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if OKYO Pharma Ltd is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine OKYO Pharma Stock
Researching OKYO Pharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 28.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.57. OKYO Pharma had not issued any dividends in recent years.
To determine if OKYO Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding OKYO Pharma's research are outlined below:
| OKYO Pharma generated a negative expected return over the last 90 days | |
| OKYO Pharma has some characteristics of a very speculative penny stock | |
| OKYO Pharma has high historical volatility and very poor performance | |
| OKYO Pharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (16.8 M) with loss before overhead, payroll, taxes, and interest of (3.6 M). | |
| OKYO Pharma Ltd currently holds about 2.06 M in cash with (9.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1. | |
| OKYO Pharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 28.0% of the company outstanding shares are owned by corporate insiders |
OKYO Pharma Quarterly Good Will |
|
OKYO Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in OKYO Pharma Ltd. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to OKYO Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of August 2023 Upcoming Quarterly Report | View | |
| 31st of March 2023 Next Fiscal Quarter End | View |
Know OKYO Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as OKYO Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading OKYO Pharma Ltd backward and forwards among themselves. OKYO Pharma's institutional investor refers to the entity that pools money to purchase OKYO Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Barclays Plc | 2024-06-30 | 961 K | Citadel Advisors Llc | 2024-09-30 | 14.9 K | Hpm Partners Llc | 2024-06-30 | 12.8 K | Geode Capital Management, Llc | 2024-09-30 | 12.1 K | Hsbc Holdings Plc | 2024-06-30 | 11.9 K | Susquehanna International Group, Llp | 2024-06-30 | 11.1 K | Ubs Group Ag | 2024-06-30 | 1.9 K | Continuum Advisory, Llc | 2024-06-30 | 50.0 |
OKYO Pharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 36.54 M.Market Cap |
|
OKYO Pharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.01) | (0.01) | |
| Return On Assets | (0.01) | (0.01) |
Determining OKYO Pharma's profitability involves analyzing its financial statements and using various financial metrics to determine if OKYO Pharma is a good buy. For example, gross profit margin measures OKYO Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of OKYO Pharma's profitability and make more informed investment decisions.
Evaluate OKYO Pharma's management efficiency
OKYO Pharma has return on total asset (ROA) of (2.9187) % which means that it has lost $2.9187 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (29.6851) %, meaning that it created substantial loss on money invested by shareholders. OKYO Pharma's management efficiency ratios could be used to measure how well OKYO Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Equity is likely to grow to 0, while Return On Tangible Assets are likely to drop (0.01). As of the 27th of November 2024, Intangible Assets is likely to grow to about 8.9 M, while Total Assets are likely to drop about 1.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.20) | (0.19) | |
| Net Current Asset Value | 42.89 | 38.12 | |
| Tangible Book Value Per Share | (0.20) | (0.19) | |
| Enterprise Value Over EBITDA | -2.7 K | -2.6 K | |
| Price Book Value Ratio | (7.34) | (7.70) | |
| Enterprise Value Multiple | -2.7 K | -2.6 K | |
| Price Fair Value | (7.34) | (7.70) | |
| Enterprise Value | 42.3 M | 40.2 M |
The strategic vision of OKYO Pharma Ltd management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Beta (3.36) |
Basic technical analysis of OKYO Stock
As of the 27th of November, OKYO Pharma holds the Semi Deviation of 4.07, risk adjusted performance of 0.0309, and Market Risk Adjusted Performance of 0.4172. In connection with fundamental indicators, the technical analysis model allows you to check available technical drivers of OKYO Pharma, as well as the relationship between them.OKYO Pharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific OKYO Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on OKYO Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases OKYO Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Denoyer Bernard over six months ago Disposition of 1000000 shares by Denoyer Bernard of OKYO Pharma at 0.1045 subject to Rule 16b-3 | ||
Cerrone Gabriele M over a year ago Acquisition or disposition of OKYO Pharma securities by Cerrone Gabriele M | ||
Brancaccio John P over a year ago Purchase by Brancaccio John P of 16670 shares of OKYO Pharma |
OKYO Pharma's Outstanding Corporate Bonds
OKYO Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. OKYO Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most OKYO bonds can be classified according to their maturity, which is the date when OKYO Pharma Ltd has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand OKYO Pharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing OKYO Pharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0309 | |||
| Market Risk Adjusted Performance | 0.4172 | |||
| Mean Deviation | 3.59 | |||
| Semi Deviation | 4.07 | |||
| Downside Deviation | 4.85 | |||
| Coefficient Of Variation | 3441.22 | |||
| Standard Deviation | 5.69 | |||
| Variance | 32.32 | |||
| Information Ratio | 0.0061 | |||
| Jensen Alpha | 0.1093 | |||
| Total Risk Alpha | (0.74) | |||
| Sortino Ratio | 0.0072 | |||
| Treynor Ratio | 0.4072 | |||
| Maximum Drawdown | 32.59 | |||
| Value At Risk | (8.65) | |||
| Potential Upside | 14.55 | |||
| Downside Variance | 23.56 | |||
| Semi Variance | 16.57 | |||
| Expected Short fall | (4.55) | |||
| Skewness | 1.67 | |||
| Kurtosis | 4.93 |
| Risk Adjusted Performance | 0.0309 | |||
| Market Risk Adjusted Performance | 0.4172 | |||
| Mean Deviation | 3.59 | |||
| Semi Deviation | 4.07 | |||
| Downside Deviation | 4.85 | |||
| Coefficient Of Variation | 3441.22 | |||
| Standard Deviation | 5.69 | |||
| Variance | 32.32 | |||
| Information Ratio | 0.0061 | |||
| Jensen Alpha | 0.1093 | |||
| Total Risk Alpha | (0.74) | |||
| Sortino Ratio | 0.0072 | |||
| Treynor Ratio | 0.4072 | |||
| Maximum Drawdown | 32.59 | |||
| Value At Risk | (8.65) | |||
| Potential Upside | 14.55 | |||
| Downside Variance | 23.56 | |||
| Semi Variance | 16.57 | |||
| Expected Short fall | (4.55) | |||
| Skewness | 1.67 | |||
| Kurtosis | 4.93 |
Consider OKYO Pharma's intraday indicators
OKYO Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of OKYO Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
OKYO Pharma time-series forecasting models is one of many OKYO Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary OKYO Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
OKYO Stock media impact
Far too much social signal, news, headlines, and media speculation about OKYO Pharma that are available to investors today. That information is available publicly through OKYO media outlets and privately through word of mouth or via OKYO internal channels. However, regardless of the origin, that massive amount of OKYO data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of OKYO Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of OKYO Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to OKYO Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive OKYO Pharma alpha.
OKYO Pharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards OKYO Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
OKYO Pharma Corporate Management
| Michael Beck | Founder | Profile | |
| Keeren Shah | Chief Officer | Profile | |
| PharmD Clementi | Chief Officer | Profile | |
| Rajkumar Patil | Chief Officer | Profile | |
| Gary Jacob | CEO Director | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OKYO Pharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OKYO Pharma. If investors know OKYO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OKYO Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.57) | Return On Assets (2.92) | Return On Equity (29.69) |
The market value of OKYO Pharma is measured differently than its book value, which is the value of OKYO that is recorded on the company's balance sheet. Investors also form their own opinion of OKYO Pharma's value that differs from its market value or its book value, called intrinsic value, which is OKYO Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OKYO Pharma's market value can be influenced by many factors that don't directly affect OKYO Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between OKYO Pharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if OKYO Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OKYO Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.